Trump Administration Moves to Loosen Marijuana Restrictions, Raising Concerns About Public Safety
Select a version of the text written from a presumed ideological perspective. This is not the original text, but a hypothetical version — how someone with that viewpoint might have phrased it. Tapping the current version again will return to the original or select cleaned version.
The Trump administration has reclassified state-licensed medical marijuana from Schedule I to Schedule III, a controversial move that acknowledges medical use and reduces regulatory barriers, but critics warn it could empower the marijuana industry and send dangerous signals about drug use.
In a major policy shift, the Trump administration has reclassified state-licensed medical marijuana from Schedule I to Schedule III under federal drug laws. This change, which acknowledges the medical use of cannabis and reduces regulatory barriers, stops short of legalizing marijuana for medical or recreational use at the federal level, but has sparked concerns about the direction of national drug policy.
Acting Attorney General Todd Blanche signed the order, stating that the Department of Justice is 'delivering on President Trump’s promise' to expand medical treatment options. Blanche emphasized that the rescheduling action will allow for research on the safety and efficacy of cannabis, aiming to provide patients with better care and doctors with more reliable information. However, critics argue that this move could open the door to further normalization of a dangerous drug.
The reclassification legitimizes medical marijuana programs in 40 states, creating an expedited system for state-licensed producers and distributors to register with the U.S. Drug Enforcement Administration. It also allows cannabis researchers to obtain state-licensed marijuana without penalty, and permits medical marijuana companies to deduct business expenses on their federal taxes—a benefit previously unavailable and now likely to be exploited by large marijuana corporations.
Critics of the decision, such as Kevin Sabet, chief executive of Smart Approaches to Marijuana, argue that while research is important, there are better ways to increase knowledge without handing out tax breaks to the powerful marijuana industry and sending a confusing message about the risks of marijuana to the public. Sabet expressed concern that policy is now being influenced by marijuana CEOs and investors, rather than prioritizing public health and safety.
The Trump administration also announced plans to initiate a broader reclassification process for marijuana, with hearings set for late June. This move follows President Trump’s directive in December to expedite the reclassification of marijuana, but many warn that such steps could undermine efforts to combat drug abuse and protect communities.